Overall, inhibition of GSK-3β enhances the β-catenin stabilization, WβC signal activation, NSC proliferation and neurogenesis in SGZ and SVZ road to use GSK-3β inhibitors to enhance stem/precursor cell therapy in PD [134,144]. This evidence concerns the gene GSK3B and Parkinson disease.